FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ander Urruticoechea

Research Profile

Disorders

Chemicals & Drugs

Physiology

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Begoña Martin-Castillo; Bruna Corominas-Faja; Silvia Cufí; Eugeni López-Bonet; José Manuel Moreno; Cristina Oliveras-Ferraros; Ander Urruticoechea; Alejandro Vazquez-Martin; Ángel G Martín; Javier A Menendez
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Sílvia Cufí; Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Ander Urruticoechea; Alejandro Vazquez-Martin; Bruna Corominas-Faja; Javier A Menendez
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Sonia Pernas; Anna Petit; María Jesús Pla; Ander Urruticoechea; Fina Climent; María Ochoa de Olza; Cati Falo; Adela Fernandez-Otega; Amparo García-Tejedor; Miguel Gil-Gil; Anna Gumà; Ana López-Ojeda; Carlos Mesia; Francisco Javier Pérez-Martin; Josep Ramon Germà
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ander Urruticoechea (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Begoña Martin-Castillo; Bruna Corominas-Faja; Silvia Cufí; Eugeni López-Bonet; José Manuel Moreno; Cristina Oliveras-Ferraros; Ander Urruticoechea; Alejandro Vazquez-Martin; Ángel G Martín; Javier A Menendez
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).
Cell cycle (Georgetown, Tex.) 2013;12(2):225-45.
2012: Sílvia Cufí; Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Ander Urruticoechea; Alejandro Vazquez-Martin; Bruna Corominas-Faja; Javier A Menendez
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Oncotarget 2012;3(12):1600-14.
2012: Sonia Pernas; Anna Petit; María Jesús Pla; Ander Urruticoechea; Fina Climent; María Ochoa de Olza; Cati Falo; Adela Fernandez-Otega; Amparo García-Tejedor; Miguel Gil-Gil; Anna Gumà; Ana López-Ojeda; Carlos Mesia; Francisco Javier Pérez-Martin; Josep Ramon Germà
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Breast cancer research and treatment 2012;134(3):1161-8.
2012: Marta Palafox; Pasquale Pellegrini; Maria Teresa Soler; Mark Tometsko; Ander Urruticoechea; Sergi Vila; Francesc Viñals; Dan Branstetter; Fina Climent; William C Dougall; Irene Ferrer; Sara Hernandez-Ortega; Purificación Muñoz; Eva González-Suárez
RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.
Cancer research 2012;72(11):2879-88.
2011: Teresa Puig; Carlos Turrado; Ander Urruticoechea; Helena Aguilar; Bellinda Benhamú; Sílvia Cufí; María Luz López-Rodríguez; Glòria Oliveras; Sílvia Ortega-Gutiérrez; Ramon Colomer
A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines.
Breast cancer research : BCR 2011;13(6):R131.
2010: Helena Aguilar; Xavier Sole; N Bonifaci; J Serra-Musach; Abul Islam; Núria López-Bigas; M Méndez-Pertuz; R L Beijersbergen; Conxi Lázaro; Ander Urruticoechea; Miguel Angel Pujana
Biological reprogramming in acquired resistance to endocrine therapy of breast cancer.
Oncogene 2010;29(45):6071-83.
2010: María Teresa Bajén; A Benítez; A Domènech; Yvonne Ricart; J Mora; P Notta; D Ramal; Ander Urruticoechea; T Soler; J Martín-Comin
[Positive sentinel node risk in relation to oestrogen receptors in breast cancer in premenopausal and postmenopausal women].
Revista española de medicina nuclear 2010;29(6):289-92.
2010: Sonia Pernas; Marta Gil; A Benítez; Maria Teresa Bajen; Fina Climent; Maria Jesús Pla; Enrique Benito; Anna Guma; Cristina Gutierrez; Aleydis Pisa; Ander Urruticoechea; Javier Pérez; Miguel Gil Gil
Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence.
Annals of surgical oncology 2010;17(3):772-7.
2010: Ander Urruticoechea; R Alemany; J Balart; A Villanueva; F Viñals; G Capellá
Recent advances in cancer therapy: an overview.
Current pharmaceutical design 2010;16(1):3-10.
2009: Anna Domènech-Vilardell; María Teresa Bajén; A Benítez; Yvonne Ricart; J Mora; Laura Rodríguez-Bel; Amparo García-Tejedor; Josefina Climent; Anna López-Ojeda; Ander Urruticoechea; Josep Martín-Comín
Removal of the internal mammary sentinel node in breast cancer.
Nuclear medicine communications 2009;30(12):962-70.
2009: Xavier Solé; Núria Bonifaci; Núria López-Bigas; Antoni Berenguer; Pilar Hernández; Oscar Reina; Christopher A Maxwell; Helena Aguilar; Ander Urruticoechea; Silvia de Sanjosé; Francesc Comellas; Gabriel Capellá; Víctor Moreno; Miguel Angel Pujana
Biological convergence of cancer signatures.
PloS one 2009;4(2):e4544.
2008: Ander Urruticoechea; Monica Arnedos; Geraldine Walsh; Mitch Dowsett; Ian E Smith
Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Breast cancer research and treatment 2008;110(3):411-6.
2008: Ander Urruticoechea; Helena Aguilar; Xavier Solé; Gabriel Capellà; Lesley-Ann Martin; Mitch Dowsett; Josep Ramon Germà-Lluch
Pre-clinical validation of early molecular markers of sensitivity to aromatase inhibitors in a mouse model of post-menopausal hormone-sensitive breast cancer.
Breast cancer research and treatment 2008;109(3):463-70.
2008: Anne Kendall; Helen Anderson; Anita K Dunbier; Alan Mackay; Tim Dexter; Ander Urruticoechea; Catherine Harper-Wynne; Mitch Dowsett
Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(4):855-63.
2008: Christopher A Maxwell; Victor Moreno; Xavier Sole; Laia Gómez; Pilar Hernández; Ander Urruticoechea; Miguel Angel Pujana
Genetic interactions: the missing links for a better understanding of cancer susceptibility, progression and treatment.
Molecular cancer 2008;7():4.
2007: Ander Urruticoechea
The oestrogen-dependent biology of breast cancer. Sensitivity and resistance to aromatase inhibitors revisited: a molecular perspective.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(12):752-9.
2007: Alan Mackay; Ander Urruticoechea; J Michael Dixon; Tim Dexter; Kerry Fenwick; Alan Ashworth; Suzanne Drury; Alexey Larionov; Oliver Young; Sharon White; William R Miller; Dean B Evans; Mitch Dowsett
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Breast cancer research : BCR 2007;9(3):R37.
2007: Pilar Hernández; Xavier Sole; Joan Valls; Victor Moreno; Gabriel Capellá; Ander Urruticoechea; Miguel Angel Pujana
Integrative analysis of a cancer somatic mutome.
Molecular cancer 2007;6():13.
2005: Ander Urruticoechea; Ian E Smith; Mitch Dowsett
Proliferation marker Ki-67 in early breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7212-20.
2005: Ander Urruticoechea; CD Archer; Laura Assersohn; RK Gregory; Mark Verrill; R Mendes; Geraldine Walsh; Ian E Smith; Stephen R D Johnston
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer.
British journal of cancer 2005;92(3):475-9.
2004: Ander Urruticoechea; Ricard Mesía; J Domínguez; C Falo; E Escalante; Ana Montes; C Sancho; Felipe Cardenal; Margarita Majem; Josep Ramon Germà
Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer.
Lung cancer (Amsterdam, Netherlands) 2004;43(2):209-14.